Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

Takeda Pharmaceuticals America, Inc.

NDC labeler codes: 47783, 54092, 59417, 63020, 64764, 68875

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

95Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
ApprovedApplicationMedicineSponsor
February 9, 2024NDA213976 Budesonide
EOHILIA
Takeda Pharms USA
November 8, 2023NDA217564 Fruquintinib
FRUZAQLA
Takeda Pharms USA
September 27, 2023BLA761133 Vedolizumab
ENTYVIO
Takeda Pharms USA
November 23, 2021NDA215596 Maribavir
LIVTENCITY
Takeda Pharms USA
December 14, 2018NDA210166 Prucalopride
MOTEGRITY
Takeda Pharms USA
August 23, 2018BLA761090 Lanadelumab-flyo
TAKHZYRO
Dyax Corp.
June 20, 2017NDA022063 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate
MYDAYIS
Takeda Pharms USA
April 28, 2017NDA208772 Brigatinib
ALUNBRIG
Takeda Pharms USA
January 28, 2017NDA208510 Lisdexamfetamine dimesylate
VYVANSE
Takeda Pharms USA
November 20, 2015NDA208462 Ixazomib
NINLARO
Takeda Pharms USA
September 24, 2014NDA204734 Lanthanum carbonate
FOSRENOL
Takeda Pharms USA
May 20, 2014BLA125476 Vedolizumab
ENTYVIO
Takeda Pharms USA
September 30, 2013NDA204447 Vortioxetine
TRINTELLIX
Takeda Pharms USA
January 25, 2013NDA022271 Alogliptin
NESINA
Takeda Pharms USA
January 25, 2013NDA022426 Alogliptin benzoate and pioglitazone hydrochloride
OSENI
Takeda Pharms USA
January 25, 2013NDA203414 Alogliptin and metformin hydrochloride
KAZANO
Takeda Pharms USA
December 21, 2012NDA203441 Teduglutide
GATTEX KIT
Takeda Pharms USA
December 14, 2012NDA203469 Ponatinib hydrochloride
ICLUSIG
Takeda Pharms USA
August 25, 2011NDA022150 Icatibant
FIRAZYR
Takeda Pharms USA
February 26, 2010BLA022575 Velaglucerase alfa
VPRIV
Shire Human Genetic
December 1, 2009BLA125277 Ecallantide
KALBITOR
Dyax Corp.
September 2, 2009NDA022037 Guanfacine
INTUNIV
Takeda Pharms USA
February 13, 2009NDA021856 Febuxostat
ULORIC
Takeda Pharms USA
January 30, 2009NDA022287 Dexlansoprazole
DEXILANT
Takeda Pharms USA
February 23, 2007NDA021977 Lisdexamfetamine dimesylate
VYVANSE
Takeda Pharms USA
Show the other 15 applications
ApprovedApplicationMedicineSponsor
January 16, 2007NDA022000 Mesalamine
LIALDA
Takeda Pharms USA
July 28, 2006NDA021925 Pioglitazone and glimepiride
DUETACT
Takeda Pharms USA
July 24, 2006BLA125151 Idursulfase
ELAPRASE
Shire
January 31, 2006NDA021908 Lubiprostone
AMITIZA
Sucampo Pharma LLC
August 29, 2005NDA021842 Pioglitazone and metformin hydrochloride
ACTOPLUS MET
Takeda Pharms USA
July 22, 2005NDA021782 Ramelteon
ROZEREM
Takeda Pharms USA
October 26, 2004NDA021468 Lanthanum carbonate
FOSRENOL
Takeda Pharms USA
May 13, 2003NDA021602 Bortezomib
VELCADE
Takeda Pharms USA
August 30, 2002NDA021428 Lansoprazole
PREVACID
Takeda Pharms USA
October 11, 2001NDA021303 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate
ADDERALL XR 10, ADDERALL XR 15, ADDERALL XR 20
Takeda Pharms USA
July 15, 1999NDA021073 Pioglitazone
ACTOS
Takeda Pharms USA
September 30, 1997NDA020712 Carbamazepine
CARBATROL
Takeda Pharms USA
March 14, 1997NDA020333 Anagrelide
AGRYLIN
Takeda Pharms USA
May 10, 1995NDA020406 Lansoprazole
PREVACID
Takeda Pharms USA
May 10, 1993NDA020049 Mesalamine
PENTASA
Takeda Pharms USA

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2019

  1. May 13, 2019 · Class II · Terminated · D-1295-2019 · Lubiprostone

    Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

    Amitiza (lubiprostone) capsules, 24 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-240-60

  2. May 13, 2019 · Class II · Terminated · D-1294-2019 · Lubiprostone

    Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

    Amitiza (lubiprostone) capsules, 8 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-080-60

2018

  1. November 6, 2018 · Class III · Terminated · D-0286-2019 · Lubiprostone

    Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.

    AMITIZA (lubiprostone) capsules 8 mcg. 60-count bottle, Rx Only. Marketed by: Sucampo Pharma Americas, LLC, Rockville MD 20850 and Takeda Pharmaceuticals America, Inc. Deerfield, IL 60015. Active Ingredient made in Japan

2017

  1. March 17, 2017 · Class II · Terminated · D-0625-2017 · Ecallantide

    Presence of Particulate Matter: Glass

    Kalbitor (ecallantide), 10mg/mL, packaged in 3 vials per Carton, Rx Only, Dynax Corp., Burlington, MA. NDC47783-101-01

2016

  1. December 2, 2016 · Class III · Terminated · D-0432-2017 · Mesalamine

    Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules

    Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81

  2. September 2, 2016 · Class III · Terminated · D-0006-2017 · Lisdexamfetamine dimesylate

    Presence of Foreign Tablets/Capsules

    Vyvanse (lisdexamfetamine dimesylate) Capsules 30 mg, 100 count bottle, Rx Only, Manufactured for: Shire US, Inc., Lexington, MA 02421, NDC 59417-103-10

2014

  1. March 14, 2014 · Class I · Terminated · D-1251-2014 · Velaglucerase alfa

    Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.

    VPRIV¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →